Aktieanalys

Egetis: First hospital in US trial activated and delayed timeline - Redeye

Redeye Publicerad: 29 Jun 2023 09:03

Redeye notes that the first hospital in the US trial with Emcitate (ReTRIACt) has been activated and that the study duration and timeline for submission, now mid-24, have been extended (to our understanding due to hospital capacity and number of treatment naïve patients). Following this update, the company will focus its efforts on Emcitate and in-house development of Aladote will be paused until submissions are finalized. We will review our estimates and return after the call at 3pm.

Länk till analysen i sin helhet: https://www.redeye.se/research/918947/egetis-first-hospital-in-us-trial-activated-and-delayed-timeline?utm_source=finwire&utm_medium=RSS

Nyheter om Egetis Therapeutics

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!